Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy
Purpose The present study was undertaken to determine factors predictive of toxicity, patterns of failure, and survival in 60 adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with combined perioperative high-dose-rate brachytherapy and external beam radiotherap...
Gespeichert in:
Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-11, Vol.81 (4), p.e529-e539 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e539 |
---|---|
container_issue | 4 |
container_start_page | e529 |
container_title | International journal of radiation oncology, biology, physics |
container_volume | 81 |
creator | San Miguel, Iñigo, M.D San Julián, Mikel, M.D Cambeiro, Mauricio, M.D Sanmamed, Miguel Fernández, M.D Vázquez-García, Blanca, M.D Pagola, Maria, M.D Gaztañaga, Miren, M.D Martín-Algarra, Salvador, M.D Martinez-Monge, Rafael, M.D |
description | Purpose The present study was undertaken to determine factors predictive of toxicity, patterns of failure, and survival in 60 adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with combined perioperative high-dose-rate brachytherapy and external beam radiotherapy. Methods and Materials The patients were treated with surgical resection and perioperative high-dose-rate brachytherapy (16 or 24 Gy) for negative and close/microscopically positive resection margins, respectively. External beam radiotherapy (45 Gy) was added postoperatively to reach a 2-Gy equivalent dose of 62.9 and 72.3 Gy, respectively. Adjuvant chemotherapy with ifosfamide and doxorubicin was given to patients with advanced high-grade tumors. Results Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%). No Grade 5 events were observed. A location in the lower limb was significant for Grade 3 or greater toxic events on multivariate analysis ( p = .013), and the tissue volume encompassed by the 150% isodose line showed a trend toward statistical significance ( p = .086). The local control, locoregional control, and distant control rate at 9 years was 77.4%, 69.5%, and 63.8%, respectively. On multivariate analysis, microscopically involved margins correlated with local control ( p = .036) and locoregional control ( p = .007) and tumor size correlated with distant metastases ( p = .004). The 9-year disease-free survival and overall survival rate was 47.0% and 61.5%, respectively. Multivariate analysis showed poorer disease-free survival rates for patients with tumors >6 cm ( p = .005) and microscopically involved margins ( p = .043), and overall survival rates decreased with increasing tumor size ( p = .011). Conclusions Grade 3 or greater wound complications can probably be decreased using meticulous treatment planning to decrease the tissue volume encompassed by the 150% isodose line, especially in lower limb locations. Microscopically involved margins remain a predictor of local and locoregional failure, despite radiation doses >70 Gy. Patients with tumors ≥6 cm and microscopically involved margins are at high risk of treatment failure and death from the development of distant metastases. |
doi_str_mv | 10.1016/j.ijrobp.2011.04.063 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22054424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301611006043</els_id><sourcerecordid>1356925165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-891fb29a965097dc87b614ef18f92ad49521fae072ea33892b540bd59c1cc8033</originalsourceid><addsrcrecordid>eNqFkktvEzEUhQcEomngHyBkiQ2LTvBjnptKafpCqtSqCYKd5fHcaZzO2MH2RM2_x5MJLNiw8chzv3vOtX2i6CPBM4JJ9nUzUxtrqu2MYkJmOJnhjL2OJqTIy5il6c830QSzDMcswCfRqXMbjAOZJ--iE0qyLGUFnrw6vQQPtlNaaO-QadDKvCip_P4MPQgfSvrw91qotrdwhoSu0X3vpekAzTujn9C87ls_wAoGiR_Kr9HSNB6tlHM9oKWwgRYHGb8GdPXiLXTB4aC17Ldgm-AoWrSyvX4OKwgP9Sh0c9hYtFoLjRZG74KHMjrAl8bBQfMBrDJBJAywA3SrntbxUIsfQyO6sEKu98HWiu1oGOzDoYLABYgOPYpamWP5ffS2Ea2DD8fvNPp-fbVa3MZ39zffFvO7WCZ57uOiJE1FS1FmKS7zWhZ5lZEEGlI0JRV1UqaUNAJwTkEwVpS0ShNc1WkpiZQFZmwafR51jfOKu3DZINfSaA3Sc0pxmiQ0CdSXkdpa86sH53mnnIS2FRpM7zhhaVbSlIR3nEbJiEprnLPQ8K1VnbB7TjAfssI3fMwKH7LCccJDVkLbp6NDX3VQ_236E44AnI8AhNvYKbDDsKAl1MoOs9ZG_c_hXwHZKq2kaJ9hD25j-uElwlm4oxzz5ZDXIa6EYJzhhLHf41bqrA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356925165</pqid></control><display><type>article</type><title>Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>San Miguel, Iñigo, M.D ; San Julián, Mikel, M.D ; Cambeiro, Mauricio, M.D ; Sanmamed, Miguel Fernández, M.D ; Vázquez-García, Blanca, M.D ; Pagola, Maria, M.D ; Gaztañaga, Miren, M.D ; Martín-Algarra, Salvador, M.D ; Martinez-Monge, Rafael, M.D</creator><creatorcontrib>San Miguel, Iñigo, M.D ; San Julián, Mikel, M.D ; Cambeiro, Mauricio, M.D ; Sanmamed, Miguel Fernández, M.D ; Vázquez-García, Blanca, M.D ; Pagola, Maria, M.D ; Gaztañaga, Miren, M.D ; Martín-Algarra, Salvador, M.D ; Martinez-Monge, Rafael, M.D</creatorcontrib><description>Purpose The present study was undertaken to determine factors predictive of toxicity, patterns of failure, and survival in 60 adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with combined perioperative high-dose-rate brachytherapy and external beam radiotherapy. Methods and Materials The patients were treated with surgical resection and perioperative high-dose-rate brachytherapy (16 or 24 Gy) for negative and close/microscopically positive resection margins, respectively. External beam radiotherapy (45 Gy) was added postoperatively to reach a 2-Gy equivalent dose of 62.9 and 72.3 Gy, respectively. Adjuvant chemotherapy with ifosfamide and doxorubicin was given to patients with advanced high-grade tumors. Results Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%). No Grade 5 events were observed. A location in the lower limb was significant for Grade 3 or greater toxic events on multivariate analysis ( p = .013), and the tissue volume encompassed by the 150% isodose line showed a trend toward statistical significance ( p = .086). The local control, locoregional control, and distant control rate at 9 years was 77.4%, 69.5%, and 63.8%, respectively. On multivariate analysis, microscopically involved margins correlated with local control ( p = .036) and locoregional control ( p = .007) and tumor size correlated with distant metastases ( p = .004). The 9-year disease-free survival and overall survival rate was 47.0% and 61.5%, respectively. Multivariate analysis showed poorer disease-free survival rates for patients with tumors >6 cm ( p = .005) and microscopically involved margins ( p = .043), and overall survival rates decreased with increasing tumor size ( p = .011). Conclusions Grade 3 or greater wound complications can probably be decreased using meticulous treatment planning to decrease the tissue volume encompassed by the 150% isodose line, especially in lower limb locations. Microscopically involved margins remain a predictor of local and locoregional failure, despite radiation doses >70 Gy. Patients with tumors ≥6 cm and microscopically involved margins are at high risk of treatment failure and death from the development of distant metastases.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2011.04.063</identifier><identifier>PMID: 21665380</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; ADULTS ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; BRACHYTHERAPY ; Brachytherapy - methods ; CHEMOTHERAPY ; Chemotherapy, Adjuvant - methods ; DEATH ; DOSE EQUIVALENTS ; DOSE RATES ; DOXORUBICIN ; Doxorubicin - administration & dosage ; External beam radiotherapy ; Extremities ; FAILURES ; Female ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; High dose rate ; Humans ; Ifosfamide - administration & dosage ; LIMBS ; Male ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; Neoplasm, Residual ; PATIENTS ; Perioperative ; PLANNING ; RADIATION DOSES ; Radiation Injuries - pathology ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiotherapy Dosage ; Sarcoma - drug therapy ; Sarcoma - pathology ; Sarcoma - radiotherapy ; Sarcoma - surgery ; SARCOMAS ; Soft tissue sarcomas ; SURGERY ; Torso ; TOXICITY ; Treatment Failure ; Tumor Burden ; WOUNDS ; Young Adult</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.e529-e539</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-891fb29a965097dc87b614ef18f92ad49521fae072ea33892b540bd59c1cc8033</citedby><cites>FETCH-LOGICAL-c477t-891fb29a965097dc87b614ef18f92ad49521fae072ea33892b540bd59c1cc8033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2011.04.063$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21665380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22054424$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>San Miguel, Iñigo, M.D</creatorcontrib><creatorcontrib>San Julián, Mikel, M.D</creatorcontrib><creatorcontrib>Cambeiro, Mauricio, M.D</creatorcontrib><creatorcontrib>Sanmamed, Miguel Fernández, M.D</creatorcontrib><creatorcontrib>Vázquez-García, Blanca, M.D</creatorcontrib><creatorcontrib>Pagola, Maria, M.D</creatorcontrib><creatorcontrib>Gaztañaga, Miren, M.D</creatorcontrib><creatorcontrib>Martín-Algarra, Salvador, M.D</creatorcontrib><creatorcontrib>Martinez-Monge, Rafael, M.D</creatorcontrib><title>Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose The present study was undertaken to determine factors predictive of toxicity, patterns of failure, and survival in 60 adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with combined perioperative high-dose-rate brachytherapy and external beam radiotherapy. Methods and Materials The patients were treated with surgical resection and perioperative high-dose-rate brachytherapy (16 or 24 Gy) for negative and close/microscopically positive resection margins, respectively. External beam radiotherapy (45 Gy) was added postoperatively to reach a 2-Gy equivalent dose of 62.9 and 72.3 Gy, respectively. Adjuvant chemotherapy with ifosfamide and doxorubicin was given to patients with advanced high-grade tumors. Results Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%). No Grade 5 events were observed. A location in the lower limb was significant for Grade 3 or greater toxic events on multivariate analysis ( p = .013), and the tissue volume encompassed by the 150% isodose line showed a trend toward statistical significance ( p = .086). The local control, locoregional control, and distant control rate at 9 years was 77.4%, 69.5%, and 63.8%, respectively. On multivariate analysis, microscopically involved margins correlated with local control ( p = .036) and locoregional control ( p = .007) and tumor size correlated with distant metastases ( p = .004). The 9-year disease-free survival and overall survival rate was 47.0% and 61.5%, respectively. Multivariate analysis showed poorer disease-free survival rates for patients with tumors >6 cm ( p = .005) and microscopically involved margins ( p = .043), and overall survival rates decreased with increasing tumor size ( p = .011). Conclusions Grade 3 or greater wound complications can probably be decreased using meticulous treatment planning to decrease the tissue volume encompassed by the 150% isodose line, especially in lower limb locations. Microscopically involved margins remain a predictor of local and locoregional failure, despite radiation doses >70 Gy. Patients with tumors ≥6 cm and microscopically involved margins are at high risk of treatment failure and death from the development of distant metastases.</description><subject>Adult</subject><subject>ADULTS</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>BRACHYTHERAPY</subject><subject>Brachytherapy - methods</subject><subject>CHEMOTHERAPY</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>DEATH</subject><subject>DOSE EQUIVALENTS</subject><subject>DOSE RATES</subject><subject>DOXORUBICIN</subject><subject>Doxorubicin - administration & dosage</subject><subject>External beam radiotherapy</subject><subject>Extremities</subject><subject>FAILURES</subject><subject>Female</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>High dose rate</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>LIMBS</subject><subject>Male</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Neoplasm, Residual</subject><subject>PATIENTS</subject><subject>Perioperative</subject><subject>PLANNING</subject><subject>RADIATION DOSES</subject><subject>Radiation Injuries - pathology</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiotherapy Dosage</subject><subject>Sarcoma - drug therapy</subject><subject>Sarcoma - pathology</subject><subject>Sarcoma - radiotherapy</subject><subject>Sarcoma - surgery</subject><subject>SARCOMAS</subject><subject>Soft tissue sarcomas</subject><subject>SURGERY</subject><subject>Torso</subject><subject>TOXICITY</subject><subject>Treatment Failure</subject><subject>Tumor Burden</subject><subject>WOUNDS</subject><subject>Young Adult</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkktvEzEUhQcEomngHyBkiQ2LTvBjnptKafpCqtSqCYKd5fHcaZzO2MH2RM2_x5MJLNiw8chzv3vOtX2i6CPBM4JJ9nUzUxtrqu2MYkJmOJnhjL2OJqTIy5il6c830QSzDMcswCfRqXMbjAOZJ--iE0qyLGUFnrw6vQQPtlNaaO-QadDKvCip_P4MPQgfSvrw91qotrdwhoSu0X3vpekAzTujn9C87ls_wAoGiR_Kr9HSNB6tlHM9oKWwgRYHGb8GdPXiLXTB4aC17Ldgm-AoWrSyvX4OKwgP9Sh0c9hYtFoLjRZG74KHMjrAl8bBQfMBrDJBJAywA3SrntbxUIsfQyO6sEKu98HWiu1oGOzDoYLABYgOPYpamWP5ffS2Ea2DD8fvNPp-fbVa3MZ39zffFvO7WCZ57uOiJE1FS1FmKS7zWhZ5lZEEGlI0JRV1UqaUNAJwTkEwVpS0ShNc1WkpiZQFZmwafR51jfOKu3DZINfSaA3Sc0pxmiQ0CdSXkdpa86sH53mnnIS2FRpM7zhhaVbSlIR3nEbJiEprnLPQ8K1VnbB7TjAfssI3fMwKH7LCccJDVkLbp6NDX3VQ_236E44AnI8AhNvYKbDDsKAl1MoOs9ZG_c_hXwHZKq2kaJ9hD25j-uElwlm4oxzz5ZDXIa6EYJzhhLHf41bqrA</recordid><startdate>20111115</startdate><enddate>20111115</enddate><creator>San Miguel, Iñigo, M.D</creator><creator>San Julián, Mikel, M.D</creator><creator>Cambeiro, Mauricio, M.D</creator><creator>Sanmamed, Miguel Fernández, M.D</creator><creator>Vázquez-García, Blanca, M.D</creator><creator>Pagola, Maria, M.D</creator><creator>Gaztañaga, Miren, M.D</creator><creator>Martín-Algarra, Salvador, M.D</creator><creator>Martinez-Monge, Rafael, M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20111115</creationdate><title>Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy</title><author>San Miguel, Iñigo, M.D ; San Julián, Mikel, M.D ; Cambeiro, Mauricio, M.D ; Sanmamed, Miguel Fernández, M.D ; Vázquez-García, Blanca, M.D ; Pagola, Maria, M.D ; Gaztañaga, Miren, M.D ; Martín-Algarra, Salvador, M.D ; Martinez-Monge, Rafael, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-891fb29a965097dc87b614ef18f92ad49521fae072ea33892b540bd59c1cc8033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>ADULTS</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>BRACHYTHERAPY</topic><topic>Brachytherapy - methods</topic><topic>CHEMOTHERAPY</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>DEATH</topic><topic>DOSE EQUIVALENTS</topic><topic>DOSE RATES</topic><topic>DOXORUBICIN</topic><topic>Doxorubicin - administration & dosage</topic><topic>External beam radiotherapy</topic><topic>Extremities</topic><topic>FAILURES</topic><topic>Female</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>High dose rate</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>LIMBS</topic><topic>Male</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Neoplasm, Residual</topic><topic>PATIENTS</topic><topic>Perioperative</topic><topic>PLANNING</topic><topic>RADIATION DOSES</topic><topic>Radiation Injuries - pathology</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiotherapy Dosage</topic><topic>Sarcoma - drug therapy</topic><topic>Sarcoma - pathology</topic><topic>Sarcoma - radiotherapy</topic><topic>Sarcoma - surgery</topic><topic>SARCOMAS</topic><topic>Soft tissue sarcomas</topic><topic>SURGERY</topic><topic>Torso</topic><topic>TOXICITY</topic><topic>Treatment Failure</topic><topic>Tumor Burden</topic><topic>WOUNDS</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>San Miguel, Iñigo, M.D</creatorcontrib><creatorcontrib>San Julián, Mikel, M.D</creatorcontrib><creatorcontrib>Cambeiro, Mauricio, M.D</creatorcontrib><creatorcontrib>Sanmamed, Miguel Fernández, M.D</creatorcontrib><creatorcontrib>Vázquez-García, Blanca, M.D</creatorcontrib><creatorcontrib>Pagola, Maria, M.D</creatorcontrib><creatorcontrib>Gaztañaga, Miren, M.D</creatorcontrib><creatorcontrib>Martín-Algarra, Salvador, M.D</creatorcontrib><creatorcontrib>Martinez-Monge, Rafael, M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>San Miguel, Iñigo, M.D</au><au>San Julián, Mikel, M.D</au><au>Cambeiro, Mauricio, M.D</au><au>Sanmamed, Miguel Fernández, M.D</au><au>Vázquez-García, Blanca, M.D</au><au>Pagola, Maria, M.D</au><au>Gaztañaga, Miren, M.D</au><au>Martín-Algarra, Salvador, M.D</au><au>Martinez-Monge, Rafael, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-11-15</date><risdate>2011</risdate><volume>81</volume><issue>4</issue><spage>e529</spage><epage>e539</epage><pages>e529-e539</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose The present study was undertaken to determine factors predictive of toxicity, patterns of failure, and survival in 60 adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with combined perioperative high-dose-rate brachytherapy and external beam radiotherapy. Methods and Materials The patients were treated with surgical resection and perioperative high-dose-rate brachytherapy (16 or 24 Gy) for negative and close/microscopically positive resection margins, respectively. External beam radiotherapy (45 Gy) was added postoperatively to reach a 2-Gy equivalent dose of 62.9 and 72.3 Gy, respectively. Adjuvant chemotherapy with ifosfamide and doxorubicin was given to patients with advanced high-grade tumors. Results Grade 3 toxic events were observed in 18 patients (30%) and Grade 4 events in 6 patients (10%). No Grade 5 events were observed. A location in the lower limb was significant for Grade 3 or greater toxic events on multivariate analysis ( p = .013), and the tissue volume encompassed by the 150% isodose line showed a trend toward statistical significance ( p = .086). The local control, locoregional control, and distant control rate at 9 years was 77.4%, 69.5%, and 63.8%, respectively. On multivariate analysis, microscopically involved margins correlated with local control ( p = .036) and locoregional control ( p = .007) and tumor size correlated with distant metastases ( p = .004). The 9-year disease-free survival and overall survival rate was 47.0% and 61.5%, respectively. Multivariate analysis showed poorer disease-free survival rates for patients with tumors >6 cm ( p = .005) and microscopically involved margins ( p = .043), and overall survival rates decreased with increasing tumor size ( p = .011). Conclusions Grade 3 or greater wound complications can probably be decreased using meticulous treatment planning to decrease the tissue volume encompassed by the 150% isodose line, especially in lower limb locations. Microscopically involved margins remain a predictor of local and locoregional failure, despite radiation doses >70 Gy. Patients with tumors ≥6 cm and microscopically involved margins are at high risk of treatment failure and death from the development of distant metastases.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21665380</pmid><doi>10.1016/j.ijrobp.2011.04.063</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3016 |
ispartof | International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (4), p.e529-e539 |
issn | 0360-3016 1879-355X |
language | eng |
recordid | cdi_osti_scitechconnect_22054424 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adult ADULTS Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use BRACHYTHERAPY Brachytherapy - methods CHEMOTHERAPY Chemotherapy, Adjuvant - methods DEATH DOSE EQUIVALENTS DOSE RATES DOXORUBICIN Doxorubicin - administration & dosage External beam radiotherapy Extremities FAILURES Female HAZARDS Hematology, Oncology and Palliative Medicine High dose rate Humans Ifosfamide - administration & dosage LIMBS Male METASTASES Middle Aged MULTIVARIATE ANALYSIS Neoplasm, Residual PATIENTS Perioperative PLANNING RADIATION DOSES Radiation Injuries - pathology Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy Dosage Sarcoma - drug therapy Sarcoma - pathology Sarcoma - radiotherapy Sarcoma - surgery SARCOMAS Soft tissue sarcomas SURGERY Torso TOXICITY Treatment Failure Tumor Burden WOUNDS Young Adult |
title | Determinants of Toxicity, Patterns of Failure, and Outcome Among Adult Patients With Soft Tissue Sarcomas of the Extremity and Superficial Trunk Treated With Greater Than Conventional Doses of Perioperative High-Dose-Rate Brachytherapy and External Beam Radiotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A00%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determinants%20of%20Toxicity,%20Patterns%20of%20Failure,%20and%20Outcome%20Among%20Adult%20Patients%20With%20Soft%20Tissue%20Sarcomas%20of%20the%20Extremity%20and%20Superficial%20Trunk%20Treated%20With%20Greater%20Than%20Conventional%20Doses%20of%20Perioperative%20High-Dose-Rate%20Brachytherapy%20and%20External%20Beam%20Radiotherapy&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=San%20Miguel,%20I%C3%B1igo,%20M.D&rft.date=2011-11-15&rft.volume=81&rft.issue=4&rft.spage=e529&rft.epage=e539&rft.pages=e529-e539&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2011.04.063&rft_dat=%3Cproquest_osti_%3E1356925165%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356925165&rft_id=info:pmid/21665380&rft_els_id=1_s2_0_S0360301611006043&rfr_iscdi=true |